Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00510913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
February 28, 1999
Completion date
September 30, 2000
Enrollment
450 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

graft rejection, kidney transplantation